VGX™-1027 anti-inflammatory drug
VGX™-1027 is an orally administered, small molecule drug for inflammatory diseases. A novel inhibitor of pro-inflammatory responses including TNF-alpha, this drug has demonstrated preclinical efficacy against Crohn’s disease and colitis, rheumatoid arthritis (RA), and Type 1 diabetes (T1D).
VGX-1027 has completed a phase I single-ascending dose, double-blind study in healthy volunteers in which the compound was generally well-tolerated. In keeping with its focus on its synthetic vaccine technology, Inovio plans to out-license this compound.
Inflammatory bowel disease is a broad term that describes conditions with chronic or recurring immune response and inflammation of the gastrointestinal tract. The two most common inflammatory bowel diseases are ulcerative colitis and Crohn’s disease. The Centers for Disease Control estimates that as many as 1.4 million persons in the United States suffer from these diseases.
There is no known pharmaceutical or surgical cure for inflammatory bowel diseases. Current treatment includes corticosteroids, antibiotics and new biologics and immune modifiers that mitigate symptoms but do not prevent or cure the disease.
In the U.S. alone, 1.3 million people suffer from RA according to the National Institute of Arthritis and Musculoskeletal Skin Diseases. With significant unmet clinical need and the progressive introduction of higher value and more effective biopharmaceuticals, the rheumatoid arthritis market is expected to more than double in value to $27 billion by 2015. Type 1 diabetes (T1D), which can be fatal if untreated, usually strikes children and young adults, although it can strike at any age. In adults, T1D accounts for 5 to 10 percent (0.9 million -1.8 million people) of all diagnosed cases of diabetes in the U.S. alone. Risk factors for T1D may be autoimmune, genetic, or environmental. No known way to prevent type 1 diabetes exists.